The results revealed that in both models, regardless of cellular origin, the group treated with CXCR2 CAR-T demonstrated a statistically significant deceleration of tumor growth from day 28 compared to the CAR-T group (Fig. 3B, D). Here, CXCR2 is linked to neoplasm.